

Apostle Inc's MiniEnrich Technology is Accepted for Publication at Royal Society of Chemistry's *Analyst*

For immediate release

San Jose, CA, July 2, 2020 – Apostle Inc is pleased to announce that the company's original and proprietary invention, termed the Apostle MiniEnrich Technology, is accepted for publication by *Analyst*, and will appear soon. (Update 08/28/20: will appear on Sept 7, 2020, vol 145, issue 17.)

Analyst is a biweekly peer-reviewed scientific journal published by the Royal Society of Chemistry of the United Kingdom, covering analytical chemistry, bioanalysis, and detection science. The journal was established in 1876.

This original scientific article is titled "High-resolution DNA size enrichment using a magnetic nano-platform and application in non-invasive prenatal testing", and is authored by the Company's Zhang *et al.*

"The fragment sizes of circulating free DNA show subtle variability from different origins, for example, fetal vs. maternal, cancer vs. normal." said David Ge, Apostle's CEO, "The current liquid biopsy technologies offer little resolution in differentiating and enriching for this small but important difference, resulting in sample rejections, test inaccuracies, and limited clinical utility of liquid biopsies. The Apostle MiniEnrich technology is invented to address this challenge and efficiently capture this subtle variability, with data showing significant enrichment of target cfDNA fragments."

"I'm thrilled to see this invention is accepted for publication at a prestigious peer-reviewed journal. This method may have the potential to rescue rejected or non-reportable clinical samples and improve test accuracy, and may enable a much broader utility of liquid biopsies." David said.

About Apostle Inc

Apostle Inc is a biotechnology company in San Jose, CA, a provider of innovative technologies and services for public health and life sciences. Apostle aims to develop innovative technologies in the space of liquid biopsy - the sampling and analysis of non-solid biological tissue, primarily blood, often utilizing circulating free DNA (cfDNA) as a biomarker. Apostle's innovations include Apostle MiniMax, a new scalable and automatable method to efficiently capture cfDNA from a standard blood draw; Apostle MagTouch, a nucleic acids isolation automation system, and Apostle MiniEnrich, a high-resolution DNA size enrichment technology using a magnetic nano-platform.

In 2020, the company responded to the COVID-19 pandemic to help our community fight together with a high quality, low cost, fast, automated, Apostle COVID-19 Viral RNA Isolation System.

More information can be found at www.apostlebio.com.
Contact: info@apostlebio.com